Immunological memory for the win! Two new studies show immunity to Coronavirus lasts AT LEAST a year, possibly a lifetime, AND improves over time, ESPECIALLY when paired with vaccination!
The first study shows those who had been previously had an infection have cells that retain a memory of the virus persist in their bone marrow and produce antibodies whenever needed, demonstrating a SARS-CoV-2 infection induces a robust antigen-specific,
long-lived humoral immune response in humans. Find that study here:…. The second study is still being reviewed before publication in Nature but found memory B-cells continue to mature and strengthen for at least 12 months after initial infection!
You can find more here:…

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Chise 🧬🦠🧫

Chise 🧬🦠🧫 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

26 May
A study from Indraprastha Apollo Hospital in Delhi on 69 HCWs vaccinated with Covishield (AZ) who tested positive post vaccination shows:
•Vaccines helped prevent severe illness and hospitalization
•NO deaths, NO ICU admissions
•B.1.617.2 was sequenced in 48% of cases
Amongst the 69 HCWs, 51 were fully vaccinated with two doses (74%) and the remaining 18 (26%) were partially immunized with a single dose, prior to being infected. The predominant infections occurred from B.1.617.2 lineage (48%), followed by B.1 and B.1.1.7 strains.
There were only two hospital admissions (2.9%) for minor symptoms, but NO ICU admissions and NO deaths, from this group. These findings are significant because more than half of the cohort were found infected with B.1.617.2 and were still protected from severe illness,
Read 7 tweets
23 May
Let’s clear up some confusion. Concerning AstraZeneca against B.1.617.2 and those reporting it is only 60% effective, let’s stop. It’s ONLY 60% at 21 days post-second dose follow-up. At the 11-12 week follow up, one would expect it to be closer to 80-90% range. Why? See here.
Also, NO, it doesn’t take AstraZeneca 12 weeks post-second dose to achieve efficacy either. So don’t get confused. Remember that rollout of second doses of AstraZeneca was later than Pfizer in the UK. In this PHE analysis from last night, most (74%) people had only just recently
(past 28 days) had their 2nd AZ doses, vs. less than half (46%) of Pfizer, and half of them had it more than 28 days ago. So for example, B.1.1.7, when you’re looking at this chart. AstraZeneca 2 doses after 28 days is 66%. AstraZeneca second dose AFTER 12 weeks is 85-90%.
Read 13 tweets
18 May
I honestly never thought I would see the day I was shamed by other academics for only having a Masters degree. I have hit a roadblock saving to be able to even pursue a PhD while I have been helping my family during COVID. Not having one doesn’t mean I am unqualified to speak.
Those who know me know how much I went through to make it through school with what I had and what my family had. I didn’t grow up with money. I am still paying off my student loans but I’m still trying and will continue to do so. I am proud of how far I have gotten.
Some have asked who and I shouldn’t be worried about shielding these people. I’m tired. I do the best I can with what I have right now. Getting a PhD is a luxury that I cannot meet the needs for yet. Image
Read 5 tweets
18 May
This is wonderful! Real-world study data out of UCL based on 8,517 people in England and Wales shows 96% of people, who had either Pfizer’s or AstraZeneca’s vaccine developed antibodies 28 to 34 days after their 1st dose. This rose to 99% within 7 to 14 days of their second dose!
Over 9 out of 10 adults in the UK who had either the Pfizer or AstraZeneca vaccine produced antibodies against the virus within a month of their first dose. None of the participants of the study had antibodies prior to their first dose of the vaccine. The study found antibody
rates initially increase quicker among those who have had the Pfizer/BioNTech vaccine than those with the Oxford/AstraZeneca. However, after one month the recipients showed almost identical antibody positivity rates.
Read 6 tweets
15 May
Extremely welcome news today! A new study from the Indraprastha Apollo Hospital in Delhi, India shows 97.38% of a total of 3,235 HCWs vaccinated with Covishield (AstraZeneca) were protected from COVID-19 infection and the chances of hospitalization after vaccination were 0.06%.
The study was designed to evaluate the frequency of breakthrough infections, and was carried out on healthcare workers who reported to Delhi's Indraprastha Apollo Hospital with symptomatic COVID-19, during the first 100 days of the vaccination drive using the Covishield vaccine.
The results of the study show that break-through infections occur only in a small percentage and these are primarily minor infections that do not lead to severe disease. There were no ICU admissions or deaths reported!
Read 5 tweets
12 May
A recent study shows that a single dose of AstraZeneca’s vaccine in HCWs previously infected with SARS-CoV-2 serves as an effective immune booster up to at least 11 months post infection and effectively neutralizes WT, and SARS-CoV-2 variants of concern P.1, B.1.1.7, AND B.1.351!
Researchers here compared spike-specific IgG and pseudo-neutralizing spike-ACE2 blocking antibodies against SARS-CoV-2 wild type and variants B.1.1.7, B.1.351, and P.1 following two doses of Pfizer’s vaccine and a single dose of AstraZeneca’s vaccine in 232 healthcare workers
with and without a previous SARS-CoV-2 infection. What they found were that post-vaccine levels of spike-specific IgG AND neutralizing antibodies against the SARS-CoV-2 wild type and all three variants of concern were similar OR indeed higher in participants receiving a single
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!